Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (201-210 of 260) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanomaKimberly R Lindsey, Linda Gritz, Richard Sherry, et al.
Scientific Reports|February 11, 2018
A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressedCheng-Chao Lin, Mahiro Kurashige, Yi Liu, et al.
Nature|September 15, 2016
Ionic immune suppression within the tumour microenvironment limits T cell effector functionRobert Eil, Suman K Vodnala, David Clever, et al.
The Journal of Clinical Investigation|January 30, 2019
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapyTori N Yamamoto, Ping-Hsien Lee, Suman K Vodnala, et al.
Science (New York, N.Y.)|March 30, 2019
T cell stemness and dysfunction in tumors are triggered by a common mechanismSuman Kumar Vodnala, Robert Eil, Rigel J Kishton, et al.
The Journal of Experimental Medicine|June 15, 2019
Mg<sup>2+</sup> regulation of kinase signaling and immune functionChryssa Kanellopoulou, Alex B George, Evan Masutani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4Peter Attia, Giao Q Phan, Ajay V Maker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanomaSteven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Nature Medicine|February 9, 2010
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunityLukas Flatz, Ahmed N Hegazy, Andreas Bergthaler, et al.
Science (New York, N.Y.)|September 2, 2006
Cancer regression in patients after transfer of genetically engineered lymphocytesRichard A Morgan, Mark E Dudley, John R Wunderlich, et al.
Pageof 26

Showing results (201-210 of 260) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanomaKimberly R Lindsey, Linda Gritz, Richard Sherry, et al.
Scientific Reports|February 11, 2018
A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressedCheng-Chao Lin, Mahiro Kurashige, Yi Liu, et al.
Nature|September 15, 2016
Ionic immune suppression within the tumour microenvironment limits T cell effector functionRobert Eil, Suman K Vodnala, David Clever, et al.
The Journal of Clinical Investigation|January 30, 2019
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapyTori N Yamamoto, Ping-Hsien Lee, Suman K Vodnala, et al.
Science (New York, N.Y.)|March 30, 2019
T cell stemness and dysfunction in tumors are triggered by a common mechanismSuman Kumar Vodnala, Robert Eil, Rigel J Kishton, et al.
The Journal of Experimental Medicine|June 15, 2019
Mg<sup>2+</sup> regulation of kinase signaling and immune functionChryssa Kanellopoulou, Alex B George, Evan Masutani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4Peter Attia, Giao Q Phan, Ajay V Maker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanomaSteven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Nature Medicine|February 9, 2010
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunityLukas Flatz, Ahmed N Hegazy, Andreas Bergthaler, et al.
Science (New York, N.Y.)|September 2, 2006
Cancer regression in patients after transfer of genetically engineered lymphocytesRichard A Morgan, Mark E Dudley, John R Wunderlich, et al.
Pageof 26